ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of its enzymatic activity by specific tyrosine kinase inhibitors has substantially improved and fundamentally changed the treatment of chronic myeloid leukaemia and enhanced cure rates in BCR-ABL-positive childhood ALL.3, 4 However, treatment of adult BCR-ABL-positive ALL remains challenging.